“And then in parallel to that, the Abbot-based sensor, Instinct, we expect to launch in the coming months, so not too far behind Simplera.”

In context

“now it feels like 15 months. So everything on track, that's all I would say on this front, Geoff. Geoffrey Martha: Okay. Que, do you want to answer the business questions that Josh had? Que Dallara: Yes, Geoff, thanks. Josh, I think you got it right. It's really a matter of timing in the first half. We're really excited about Simplera, and you can see that we're achieving double-digit growth in the international markets where Simplera has been launched. And in the U.S., the demand is absolutely there. So we have this dynamic where patients are waiting for the new CGMs. And to give you a sense of how we're ramping up production, we're going to be producing double what we made in Q1 and in the second half double what we're making in the first half. So production is ramping up really nicely. And then in parallel to that, the Abbot-based sensor, Instinct, we expect to launch in the coming months, so not too far behind Simplera. And to put it in context, it's actually a very big moment for us because we're now going to have 2 competitive sensors on the market, giving patients choice, significant improvements in form factor and days of wear. And so really, it's a matter of timing and why I'm actually extremely confident that we'll see growth acceleration in the second half. And then you asked about what's left to get Instinct over the line, we told you that we submitted for ACE and iAGC back in April. We got ACE approved in July. So our expectation is that we'll be in a very strong position to launch in the coming months. Geoffrey Martha: Yes. Look, I'd summarize it. There's, however you want to phrase it, a super cycle of innovation here that Diabetes has. So on the very front end of -- and we think this transact”